Otsuka Reports Phase 3b SIMTRIYO Data in ADHD and Anxiety
PRINCETON, N.J. and TOKYO, Japan — September 18, 2026 Otsuka Pharmaceutical presented new Phase 3b results for SIMTRIYO® (centanafadine)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PRINCETON, N.J. and TOKYO, Japan — September 18, 2026 Otsuka Pharmaceutical presented new Phase 3b results for SIMTRIYO® (centanafadine)...
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
Shanghai and Hong Kong, PRC, September 21, 2026 Antengene Corporation Limited has announced the dosing of the first patient...
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
NEW YORK — September 10, 2026 Definium Therapeutics, Inc. announced plans to present six posters and an invited oral...
Titusville, New Jersey, U.S., September 8, 2026 Johnson & Johnson is set to present new clinical and real-world evidence...
